{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:55:19Z","timestamp":1791842119858,"version":"4.3.4"},"reference-count":47,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies. However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy. We hypothesized that small-molecule\u2013induced BTK degradation may overcome some of the limitations of traditional enzymatic inhibitors. Here, we demonstrate that BTK degradation results in potent suppression of signaling and proliferation in cancer cells and that BTK degraders efficiently degrade C481S-BTK. Moreover, we discovered DD-03-171, an optimized lead compound that exhibits enhanced antiproliferative effects on mantle cell lymphoma (MCL) cells in vitro by degrading BTK, IKFZ1, and IKFZ3 as well as efficacy against patient-derived xenografts in vivo. Thus, \u201ctriple degradation\u201d may be an effective therapeutic approach for treating MCL and overcoming ibrutinib resistance, thereby addressing a major unmet need in the treatment of MCL and other B-cell lymphomas.<\/jats:p>","DOI":"10.1182\/blood-2018-07-862953","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T22:35:12Z","timestamp":1544740512000},"page":"952-961","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":163,"title":["Bruton tyrosine kinase degradation as a therapeutic strategy for cancer"],"prefix":"10.1182","volume":"133","author":[{"given":"Dennis","family":"Dobrovolsky","sequence":"first","affiliation":[{"name":"Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;"},{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Morrow","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine","family":"Leahy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Faust","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw P.","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Donovan","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengnian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and"},{"name":"Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston MA;"},{"name":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2020021109074346200_B1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton\u2019s tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"2020021109074346200_B2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/1074-7613(95)90114-0","article-title":"Defective B cell development and function in Btk-deficient mice","volume":"3","author":"Khan","year":"1995","journal-title":"Immunity"},{"issue":"1","key":"2020021109074346200_B3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4049\/jimmunol.159.1.135","article-title":"xid affects events leading to B cell cycle entry","volume":"159","author":"Brorson","year":"1997","journal-title":"J Immunol"},{"issue":"7","key":"2020021109074346200_B4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1084\/jem.187.7.1081","article-title":"Transgene expression of bcl-xL permits anti-immunoglobulin (Ig)-induced proliferation in xid B cells","volume":"187","author":"Solvason","year":"1998","journal-title":"J Exp Med"},{"issue":"8","key":"2020021109074346200_B5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1517\/14728222.2011.585971","article-title":"Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man","volume":"15","author":"Hendriks","year":"2011","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"2020021109074346200_B6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40266-017-0468-4","article-title":"Current status of Bruton\u2019s tyrosine kinase inhibitor development and use in B-Cell malignancies","volume":"34","author":"Aw","year":"2017","journal-title":"Drugs Aging"},{"issue":"1","key":"2020021109074346200_B7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"6","key":"2020021109074346200_B8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2020021109074346200_B9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2020021109074346200_B10","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2016-04-711176","article-title":"HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma","volume":"128","author":"Jacobson","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020021109074346200_B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/15748928113089990031","article-title":"HSP90 inhibitors: current development and potential in cancer therapy","volume":"9","author":"Sidera","year":"2014","journal-title":"Recent Patents Anticancer Drug Discov"},{"issue":"6","key":"2020021109074346200_B12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem Biol"},{"issue":"6241","key":"2020021109074346200_B13","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"1","key":"2020021109074346200_B14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"2","key":"2020021109074346200_B15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat Chem Biol"},{"issue":"4","key":"2020021109074346200_B16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41589-018-0010-y","article-title":"Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands","volume":"14","author":"Gechijian","year":"2018","journal-title":"Nat Chem Biol"},{"issue":"4","key":"2020021109074346200_B17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10555-017-9698-5","article-title":"Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors","volume":"36","author":"Driscoll","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"2020021109074346200_B18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"5971","key":"2020021109074346200_B19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"6168","key":"2020021109074346200_B20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"6168","key":"2020021109074346200_B21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"7","key":"2020021109074346200_B22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat Chem Biol"},{"issue":"18","key":"2020021109074346200_B23","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","article-title":"BTKCys481Ser drives ibrutinib resistance via ERK1\/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020021109074346200_B24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"2020021109074346200_B25","doi-asserted-by":"crossref","first-page":"e38430","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"eLife"},{"key":"2020021109074346200_B26","unstructured":"R Core Team. A Language and Environment for Statistical Computing. http:\/\/www.R-project.org\/. Accessed 1 November, 2017."},{"issue":"7","key":"2020021109074346200_B27","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2020021109074346200_B28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice [published correction appears in Cancer Cell. 2016;30(1):183]","volume":"29","author":"Townsend","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"2020021109074346200_B29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2020021109074346200_B30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molcel.2017.06.004","article-title":"BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment","volume":"67","author":"Winter","year":"2017","journal-title":"Mol Cell"},{"issue":"21","key":"2020021109074346200_B31","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199405263302104","article-title":"Brief report: a point mutation in the SH2 domain of Bruton\u2019s tyrosine kinase in atypical X-linked agammaglobulinemia","volume":"330","author":"Saffran","year":"1994","journal-title":"N Engl J Med"},{"issue":"7239","key":"2020021109074346200_B32","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"issue":"1","key":"2020021109074346200_B33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10","key":"2020021109074346200_B34","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations","volume":"11","author":"Johnson","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"29","key":"2020021109074346200_B35","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2020021109074346200_B36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"2020021109074346200_B37","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood-2016-01-695098","article-title":"HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020021109074346200_B38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"issue":"10121","key":"2020021109074346200_B39","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"22","key":"2020021109074346200_B40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V128.22.148.148","article-title":"Ibrutinib-lenalidomide-rituximab in patients with relapsed\/refractory mantle cell lymphoma: first results from the Nordic Lymphoma Group MCL6 (PHILEMON) phase II trial [abstract]","volume":"128","author":"Jerkeman","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2020021109074346200_B41","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1021\/ac502040v","article-title":"MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes","volume":"86","author":"McAlister","year":"2014","journal-title":"Anal Chem"},{"issue":"26","key":"2020021109074346200_B42","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"issue":"7","key":"2020021109074346200_B43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"issue":"31","key":"2020021109074346200_B44","doi-asserted-by":"crossref","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2020021109074346200_B45","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.4049\/jimmunol.1301553","article-title":"Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis","volume":"191","author":"Rankin","year":"2013","journal-title":"J Immunol"},{"issue":"5","key":"2020021109074346200_B46","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/092986708783503212","article-title":"From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage","volume":"15","author":"Petrelli","year":"2008","journal-title":"Curr Med Chem"},{"issue":"13","key":"2020021109074346200_B47","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1084\/jem.20131735","article-title":"Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals","volume":"210","author":"Heizmann","year":"2013","journal-title":"J Exp Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/9\/952\/1558208\/blood862953.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/9\/952\/1558208\/blood862953.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:49:26Z","timestamp":1775306966000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/9\/952\/260651\/Bruton-tyrosine-kinase-degradation-as-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,2,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-07-862953","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]}}}